Table 10.

Test 3: Sensitivity Analysis – Changing CATIE Relapse Risk Ratios

	Olanzapine/CATIE Ratio	Cost-Neutral Ratio	Cost-Effective Ratio (ICER @ $50000)
RIS	0.64*	0.65	0.73 ($45,385)
QUE	0.44	0.88	0.89 ($60,767)
ZIP	0.57	0.75	0.80 ($43,236)
ARIP	0.57	0.77	0.80 ($44,187)

*Base case ratio from CATIE Phase 1 [23] which reported hospitalization risk ratios normalized to 1 person year of exposure: RIS = 0.45, OLZ = 0.29 thus olanzapine/risperidone = 0.64.

CATIE = Clinical Antipsychotic Trials of Intervention Effectiveness; ICER = incremental cost-effectiveness ratio; RIS = risperidone; QUE = quetiapine; ZIP = ziprasidone; ARIP = aripiprazole